BioCentury | Jul 10, 2018
Distillery Therapeutics


INDICATION: Blistering disorder Patient sample and cell culture studies suggest the generic antibiotic gentamicin could help treat Herlitz junctional epidermolysis bullosa, a blistering disorder caused by loss-of-function mutations in LAMB3. In patient-derived junctional epidermolysis cells...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

New Therapeutic Targets and Biomarkers: November 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Nov 9, 2017
Preclinical News

LAMB3 gene therapy successfully treats epidermolysis bullosa

In a paper published in Nature , researchers from Ruhr University Bochum and colleagues described the successful regeneration and engraftment of almost the entire epidermis of a patient with junctional epidermolysis bullosa (JEB) using laminin beta...
BioCentury | Oct 12, 2017
Emerging Company Profile

Chemo-proof T cells

T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven’t produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant γδ T cells with chemotherapy, Incysus Ltd. has...
BioCentury | Apr 9, 2015
Distillery Therapeutics

Therapeutics: Triggering receptor expressed on myeloid cells 2 (TREM2)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting TREM2 could help treat AD. In two mouse models of AD, TREM2 was expressed on monocytes of peripheral origin that accumulate around β-amyloid...
BioCentury | May 30, 2013
Cover Story

RON's new role

A Utah team has shown that inhibiting the kinase RON could fight cancer metastasis by stimulating an antitumor immune response. 1 The findings build a case for directed drug discovery efforts against the target, which...
BioCentury | Apr 15, 2013
Company News

PPL, Roslin Institute other research news

PPL and Roslin scientists produced 5 transgenic sheep using their nuclear transfer procedure (see BioCentury Feb. 24). Fibroblasts cultured from Poll Dorset sheep were transfected with a gene encoding a human plasma protein or a...
BioCentury | Jul 23, 2012

In like a lion . . .

Human Genome Sciences Inc. (NASDAQ:HGSI) roared into biotech in the early 1990s with its genomics database. But it's going out like a lamb after GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to acquire the biotech last week...
BioCentury | May 24, 2012
Targets & Mechanisms

Getting selective for gamma

Cellzome AG and Exelixis Inc. have independently designed the first highly selective inhibitors of the g-isoform of phosphoinositide 3-kinase . 1,2 Exelixis plans to out-license its inhibitors, whereas last week's acquisition of Cellzome by GlaxoSmithKline plc...
BioCentury | Sep 22, 2011
Cover Story

Finding the repurpose

A Stanford University team has used a computational approach to analyze publicly available gene expression profiles and identified two drug repurposing opportunities. 1,2 The researchers found that the anticonvulsant topiramate could have use in inflammatory...
Items per page:
1 - 10 of 51